BRPI0417689A - método para conjugar um imonógeno de peptìdeo, composição, conjugado, composição imunogênica, método para induzir uma resposta imune em um indivìduo mamìfero, e, uso do conjugado - Google Patents
método para conjugar um imonógeno de peptìdeo, composição, conjugado, composição imunogênica, método para induzir uma resposta imune em um indivìduo mamìfero, e, uso do conjugadoInfo
- Publication number
- BRPI0417689A BRPI0417689A BRPI0417689-8A BRPI0417689A BRPI0417689A BR PI0417689 A BRPI0417689 A BR PI0417689A BR PI0417689 A BRPI0417689 A BR PI0417689A BR PI0417689 A BRPI0417689 A BR PI0417689A
- Authority
- BR
- Brazil
- Prior art keywords
- conjugate
- composition
- immunogenic
- peptide
- carrier
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53048103P | 2003-12-17 | 2003-12-17 | |
| PCT/US2004/044093 WO2005058941A2 (en) | 2003-12-17 | 2004-12-17 | Aβ IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0417689A true BRPI0417689A (pt) | 2007-04-03 |
| BRPI0417689A8 BRPI0417689A8 (pt) | 2017-04-25 |
Family
ID=34700143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0417689A BRPI0417689A8 (pt) | 2003-12-17 | 2004-12-17 | Método para conjugar um imonógeno de peptídeo, composição, conjugado, composição imunogênica, método para induzir uma resposta imune em um indivíduo mamífero, e, uso do conjugado |
Country Status (26)
| Country | Link |
|---|---|
| US (5) | US8227403B2 (pt) |
| EP (4) | EP2479184A3 (pt) |
| JP (1) | JP4696079B2 (pt) |
| KR (2) | KR101201120B1 (pt) |
| CN (1) | CN1934127B (pt) |
| AR (1) | AR047062A1 (pt) |
| AU (2) | AU2004299512B2 (pt) |
| BR (1) | BRPI0417689A8 (pt) |
| CA (1) | CA2549552A1 (pt) |
| CR (1) | CR8445A (pt) |
| DK (1) | DK2336147T3 (pt) |
| EA (2) | EA009559B1 (pt) |
| EC (1) | ECSP066646A (pt) |
| ES (1) | ES2474173T3 (pt) |
| IL (2) | IL176250A (pt) |
| MX (1) | MXPA06006821A (pt) |
| MY (1) | MY144231A (pt) |
| NO (1) | NO20062765L (pt) |
| PH (1) | PH12011502391A1 (pt) |
| PL (1) | PL2336147T3 (pt) |
| PT (1) | PT2336147E (pt) |
| SG (2) | SG182189A1 (pt) |
| SI (1) | SI2336147T1 (pt) |
| TW (2) | TWI379839B (pt) |
| UA (1) | UA84728C2 (pt) |
| WO (1) | WO2005058941A2 (pt) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| US7588766B1 (en) | 2000-05-26 | 2009-09-15 | Elan Pharma International Limited | Treatment of amyloidogenic disease |
| US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| US20050059802A1 (en) * | 1998-04-07 | 2005-03-17 | Neuralab Ltd | Prevention and treatment of amyloidogenic disease |
| US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| KR20050118669A (ko) * | 2003-02-01 | 2005-12-19 | 뉴랄랩 리미티드 | 가용성 a-베타에 대한 항체를 생성하기 위한 능동 면역화 |
| TWI306458B (en) * | 2003-05-30 | 2009-02-21 | Elan Pharma Int Ltd | Humanized antibodies that recognize beta amyloid peptide |
| SG149013A1 (en) * | 2003-12-17 | 2009-01-29 | Wyeth Corp | Immunogenic peptide carrier conjugates and methods of producing same |
| SI2336147T1 (sl) | 2003-12-17 | 2014-08-29 | Janssen Alzheimer Immunotherapy | Konjugati nosilcev a beta imunogenih peptidov in postopki izdelave istih |
| JP2007522119A (ja) * | 2004-01-28 | 2007-08-09 | キュリックス エーピーエス | アミロイド関連疾患用ワクチンとしてのアミロイドタンパク質のコンジュゲート |
| EA200700751A1 (ru) * | 2004-10-05 | 2008-06-30 | Элан Фарма Интернэшнл Лимитед | Способы и композиции для улучшения продуцирования рекомбинантного белка |
| ES2396555T3 (es) | 2004-12-15 | 2013-02-22 | Janssen Alzheimer Immunotherapy | Anticuerpos que reconocen péptido beta amiloide |
| EP1838348B1 (en) | 2004-12-15 | 2013-06-26 | Janssen Alzheimer Immunotherapy | Humanized amyloid beta antibodies for use in improving cognition |
| GT200600031A (es) * | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| BRPI0611600B8 (pt) * | 2005-06-17 | 2021-05-25 | Wyeth Corp | método para purificação de uma proteína tendo uma região fc a partir de um líquido fonte compreendendo a proteína e uma ou mais impurezas, e kit |
| US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| RU2498999C2 (ru) | 2006-07-14 | 2013-11-20 | Ац Иммуне Са | Гуманизированное антитело к амилоиду бета |
| US9481912B2 (en) | 2006-09-12 | 2016-11-01 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and identifying nucleic acid sequences in biological samples |
| US8097419B2 (en) | 2006-09-12 | 2012-01-17 | Longhorn Vaccines & Diagnostics Llc | Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009 |
| US8080645B2 (en) * | 2007-10-01 | 2011-12-20 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection/transport compositions and methods |
| US8652782B2 (en) | 2006-09-12 | 2014-02-18 | Longhorn Vaccines & Diagnostics, Llc | Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids |
| WO2008124646A2 (en) * | 2007-04-06 | 2008-10-16 | The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services | Use of amyloid proteins as vaccine scaffolds |
| US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
| US8106015B2 (en) * | 2007-04-20 | 2012-01-31 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Method for enhancing immune response with peptide |
| US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| ES2498040T3 (es) | 2007-07-27 | 2014-09-24 | Janssen Alzheimer Immunotherapy | Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados |
| US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
| US11041215B2 (en) | 2007-08-24 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | PCR ready compositions and methods for detecting and identifying nucleic acid sequences |
| CA2697373C (en) | 2007-08-27 | 2019-05-21 | Longhorn Vaccines & Diagnostics, Llc | Immunogenic compositions and methods |
| US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
| AU2008343745B2 (en) | 2007-10-01 | 2012-05-10 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection and transport system and methods of use |
| US11041216B2 (en) | 2007-10-01 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples |
| PL2238166T3 (pl) | 2007-10-05 | 2014-07-31 | Genentech Inc | Zastosowanie przeciwciała anty-Beta amyloidowego w chorobach oczu |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| ITNA20080006A1 (it) * | 2008-01-28 | 2009-07-29 | Consiglio Nazionale Ricerche | Proteine chimeriche capaci di formare particelle virus-like, che contengono sequenze peptidiche del beta-amiloide e la componente e2 della alfachetoacido deidrogenasi di "geobacillus stearothermophilus", utili per l'induzione di una risposta anticorp |
| US9498522B2 (en) * | 2008-08-07 | 2016-11-22 | Mercia Pharma Inc. | Immunotherapeutic compositions for the treatment of alzheimer'S disease |
| US8512709B2 (en) | 2008-10-16 | 2013-08-20 | The Chemo-Sero-Therapeutic Research Institue | Modified amyloid β peptide |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| DE102008037564A1 (de) * | 2008-11-19 | 2010-05-20 | Forschungszentrum Jülich GmbH | Zusammensetzung zur Herstellung von anti-Amyloid beta-Peptid-Antikörpern mit D-Peptiden |
| EP2258398A1 (en) | 2009-05-26 | 2010-12-08 | Araclón Biotech, S. L. | Albumin-amyloid peptide conjugates and uses thereof |
| PH12012501744A1 (en) | 2010-03-03 | 2021-08-09 | Boehringer Ingelheim Int | Biparatopic abeta binding polypeptides |
| US9221900B2 (en) | 2010-07-30 | 2015-12-29 | Ac Immune S.A. | Methods for identifying safe and functional humanized antibodies |
| US20120328605A1 (en) * | 2010-10-27 | 2012-12-27 | Daniel Larocque | Compositions and uses |
| GB201101331D0 (en) * | 2011-01-26 | 2011-03-09 | Glaxosmithkline Biolog Sa | Compositions and uses |
| CN102279269A (zh) * | 2011-04-12 | 2011-12-14 | 王贤俊 | 胱抑素c检测剂盒的制备方法 |
| KR101839496B1 (ko) * | 2011-06-01 | 2018-03-19 | 시아먼 유니버시티 | 디프테리아 독소 무독성 돌연변이 씨알엠197 또는 그의 단편을 포함하는 융합 단백질 |
| US8906382B2 (en) * | 2011-07-19 | 2014-12-09 | New York University | Method for treating amyloid disease |
| GB201113570D0 (en) * | 2011-08-05 | 2011-09-21 | Glaxosmithkline Biolog Sa | Vaccine |
| WO2013021353A1 (en) * | 2011-08-11 | 2013-02-14 | Bar-Ilan University | Surface modified proteinaceous spherical particles and uses thereof |
| CA2811188C (en) * | 2011-09-23 | 2020-04-28 | Andrea Pfeifer | Vaccine therapy |
| CA3207612A1 (en) | 2012-01-26 | 2013-08-01 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
| SI2668959T1 (sl) * | 2012-05-31 | 2015-03-31 | Innavirvax Genopole Enterprises | Imunogenske spojine, ki vsebujejo HIV gp41 peptid, spojen z nosilnim proteinom CRM197 |
| KR101451797B1 (ko) * | 2012-11-07 | 2014-10-16 | 가천대학교 산학협력단 | 멀티머-형성 폴리펩타이드의 멀티머 정량분석을 위한 표준 단백질 복합체 |
| EP3028048B1 (en) * | 2013-07-31 | 2018-09-26 | BioVentures, LLC | Compositions for treating and preventing cancer targeting tumor associated carbohydrate antigens |
| EP2870974A1 (en) * | 2013-11-08 | 2015-05-13 | Novartis AG | Salmonella conjugate vaccines |
| US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| CN104069504B (zh) | 2014-05-11 | 2019-09-24 | 江苏康泰生物医学技术有限公司 | 一种增强多糖蛋白结合物免疫原性的方法 |
| EP3156423B1 (en) * | 2014-06-11 | 2025-02-19 | Riken | Multiplex alloantigenic peptide |
| US9107906B1 (en) | 2014-10-28 | 2015-08-18 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
| EP3294448A4 (en) | 2015-05-14 | 2018-12-12 | Longhorn Vaccines and Diagnostics, LLC | Rapid methods for the extraction of nucleic acids from biological samples |
| JP2019526274A (ja) * | 2016-07-21 | 2019-09-19 | ヴァック4オール・ピーティーイー・リミテッドVac4All Pte. Ltd. | 抗マラリアワクチンとしてのバイオ融合タンパク質 |
| US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
| CN112088014B (zh) | 2018-02-28 | 2026-03-24 | 华盛顿大学 | 自组装纳米结构疫苗 |
| WO2020257315A1 (en) * | 2019-06-18 | 2020-12-24 | Citranvi Biosciences, Llc | Multiple antigen protein displayed adjuvant systems |
| US12485166B2 (en) | 2020-02-06 | 2025-12-02 | Longhorn Vaccines And Diagnostics, Llc | Vaccines for the treatment and prevention of zoonotic infections |
| KR20230091978A (ko) | 2020-10-20 | 2023-06-23 | 롱혼 백신즈 앤드 다이어그나스틱스, 엘엘씨 | 면역원성 항원 |
| CN116710138A (zh) * | 2020-11-09 | 2023-09-05 | 国立大学法人鹿儿岛大学 | 肽交联剂以及通过该交联剂交联的交联肽 |
| KR20230107621A (ko) | 2020-11-13 | 2023-07-17 | 아이코사백스, 인크. | 메타뉴모바이러스에 대한 단백질-기반 나노입자 백신 |
| WO2022140289A1 (en) | 2020-12-21 | 2022-06-30 | Cornell University | Peptide-linked drug delivery system |
| BE1029148B1 (fr) * | 2021-02-26 | 2022-09-26 | Curavac Europe | Vaccin pour un traitement therapeutique ou prophylactique de la myastenie grave |
| BE1029149B1 (fr) * | 2021-02-26 | 2022-09-26 | Nicolas Havelange | Protéine porteuse pour antigene peptidique |
| CN114137203A (zh) * | 2021-10-21 | 2022-03-04 | 广州万孚生物技术股份有限公司 | 抗原与碱性磷酸酶结合物的制备方法 |
| JP2025517362A (ja) | 2022-05-17 | 2025-06-05 | アイコサバックス, インコーポレイテッド | パラミクソウイルス用の多価ワクチン及びその使用 |
| CN116059401B (zh) * | 2023-02-22 | 2025-04-29 | 东南大学 | 一种双功能纳米探针及其制备方法和应用 |
| TW202539728A (zh) * | 2023-11-16 | 2025-10-16 | 美商默沙東有限責任公司 | 肽共軛物疫苗組合物及治療阿茲海默氏症之方法 |
Family Cites Families (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2982084A (en) * | 1957-05-29 | 1961-05-02 | Ebauches Sa | Alarm device |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4902506A (en) | 1983-07-05 | 1990-02-20 | The University Of Rochester | Immunogenic conjugates |
| US5360897A (en) | 1981-08-31 | 1994-11-01 | The University Of Rochester | Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad |
| US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5126131A (en) * | 1983-01-24 | 1992-06-30 | The Johns Hopkins University | Therapeutic suppression of specific immune responses by administration of antigen-competitive conjugates. |
| US4882317A (en) * | 1984-05-10 | 1989-11-21 | Merck & Co., Inc. | Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4666829A (en) | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
| US5078996A (en) | 1985-08-16 | 1992-01-07 | Immunex Corporation | Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
| US5245015A (en) * | 1991-04-26 | 1993-09-14 | Tanox Biosystems, Inc. | Monoclonal antibodies which neutralize HIV-1 through reaction with a conformational epitope in vitro |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US5089603A (en) | 1989-06-21 | 1992-02-18 | Tanox Biosystems, Inc. | Antigenic epitopes present on membrane-bound but not secreted iga |
| US5785973A (en) | 1988-02-01 | 1998-07-28 | Praxis Biologics, Inc. | Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines |
| US5192540A (en) | 1988-04-19 | 1993-03-09 | American Cyanamid Company | Haemophilus influenzae type b oxidized polysaccharide-outer membrane protein conjugate vaccine |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| CA2006700A1 (en) | 1989-01-17 | 1990-07-17 | Antonello Pessi | Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines |
| IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
| ES2109945T3 (es) | 1990-06-01 | 1998-02-01 | Chiron Corp | Composiciones y procedimientos para identificar moleculas biologicamente activas. |
| US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
| CA2059692C (en) * | 1991-01-28 | 2004-11-16 | Peter J. Kniskern | Pneumoccoccal polysaccharide conjugate vaccine |
| IL101715A (en) | 1991-05-02 | 2005-06-19 | Amgen Inc | Recombinant dna-derived cholera toxin subunit analogs |
| EP0604552B1 (en) | 1991-09-18 | 1997-02-12 | Affymax Technologies N.V. | Method of synthesizing diverse collections of oligomers |
| WO1993013302A1 (de) | 1991-12-23 | 1993-07-08 | Michael Zoche | Motor mit einer vorrichtung zur entölung |
| EP0625910B1 (en) * | 1992-02-11 | 2003-07-23 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Dual carrier immunogenic construct |
| HUT72495A (en) | 1992-10-01 | 1996-05-28 | Cold Spring Harbor Lab | Complex combinatorial chemical libraries encoded with tags |
| DK0616034T3 (da) | 1993-03-05 | 2005-02-21 | Wyeth Corp | Plasmid til fremstilling af CRM-protein og diphtheria toxin |
| CN1135181A (zh) | 1993-09-14 | 1996-11-06 | Cytel有限公司 | 使用泛dr结合肽改变免疫应答 |
| JPH09508353A (ja) | 1993-11-02 | 1997-08-26 | アフィマックス テクノロジーズ ナムローゼ フェンノートシャップ | 分子多様性の合成及びスクリーニング |
| US5571515A (en) | 1994-04-18 | 1996-11-05 | The Wistar Institute Of Anatomy & Biology | Compositions and methods for use of IL-12 as an adjuvant |
| JPH10500112A (ja) | 1994-05-06 | 1998-01-06 | ファーマコピーア,インコーポレイテッド | 組合せ ジヒドロベンゾピラン ライブラリー |
| US5663046A (en) | 1994-06-22 | 1997-09-02 | Pharmacopeia, Inc. | Synthesis of combinatorial libraries |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| IL115933A0 (en) | 1995-11-09 | 1996-01-31 | Oramir Semiconductor Ltd | Process and apparatus for oblique beam revolution for the effective laser stripping of sidewalls |
| NZ322175A (en) | 1995-11-10 | 1999-02-25 | Elan Corp Plc | Peptides which enhance transport across tissues and methods of identifying the same |
| CA2745736C (en) | 1996-10-23 | 2016-11-22 | The Trustees Of The University Of Pennsylvania | Immunotherapy and improved vaccines |
| US6962984B2 (en) | 1996-12-05 | 2005-11-08 | Nihon University | IgA nephropathy-related DNA |
| PT848011E (pt) | 1996-12-16 | 2001-08-30 | Staat Nl Verteg Door Min Welzi | Metodo para acoplar polisacaridos a proteinas |
| US5877220A (en) * | 1997-03-06 | 1999-03-02 | Genta, Incorporated | Amide-based oligomeric cationic lipids |
| US20020086847A1 (en) * | 1997-04-09 | 2002-07-04 | Mindset Biopharmaceuticals (Usa) | Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
| US7588766B1 (en) * | 2000-05-26 | 2009-09-15 | Elan Pharma International Limited | Treatment of amyloidogenic disease |
| US6710226B1 (en) | 1997-12-02 | 2004-03-23 | Neuralab Limited | Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics |
| TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
| US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| GB2333706A (en) | 1998-02-02 | 1999-08-04 | Merck & Co Inc | Method for increasing muscle mass in animals |
| WO1999043839A1 (en) | 1998-02-27 | 1999-09-02 | The Trustees Of The University Of Pennsylvania | Vaccines, immunotherapeutics and methods for using the same |
| US6645503B1 (en) * | 1998-03-10 | 2003-11-11 | Wyeth Holdings Corporation | Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria |
| CA2264970A1 (en) | 1998-03-10 | 1999-09-10 | American Cyanamid Company | Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria |
| US20050059591A1 (en) | 1998-04-07 | 2005-03-17 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US20050059802A1 (en) | 1998-04-07 | 2005-03-17 | Neuralab Ltd | Prevention and treatment of amyloidogenic disease |
| JP4673974B2 (ja) | 1998-09-30 | 2011-04-20 | ワイス・ホールディングズ・コーポレイション | アジュバントとしての変異コレラホロトキシン |
| US6245015B1 (en) * | 1998-12-07 | 2001-06-12 | General Electric Company | Photosonic diffusion wave-based tumor detector |
| WO2000050077A1 (en) * | 1999-02-25 | 2000-08-31 | Smithkline Beecham Biologicals S.A. | Immunogens comprising a peptide and a carrier derived from h.influenzae protein d |
| US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
| US6945135B1 (en) * | 1999-09-09 | 2005-09-20 | L. H. Thomson Company, Inc. | Bicycle stem for enlarged handlebar portions and associated methods |
| GB9925559D0 (en) * | 1999-10-28 | 1999-12-29 | Smithkline Beecham Biolog | Novel method |
| HK1049279A1 (zh) * | 1999-11-29 | 2003-05-09 | Neurochem (International) Limited | 预防及治疗阿尔茨海默病(早老性痴呆)及淀粉样蛋白有关的病之疫苗 |
| WO2001062284A2 (en) | 2000-02-21 | 2001-08-30 | Pharmexa A/S | Novel method for down-regulation of amyloid |
| US20030190322A1 (en) * | 2000-03-31 | 2003-10-09 | Peter Kaastrup | Immunostimulating properties of a fragment of tgf-beta |
| ATE286072T1 (de) * | 2000-05-22 | 2005-01-15 | Univ New York | Synthetische immunogene jedoch nicht amyloidogene peptide, die homolog zu amyloid beta sind und deren verwendung zur induktion einer immunantwort gegen amyloid beta und amyloidaggregate |
| CA2409287A1 (en) | 2000-06-02 | 2001-12-13 | Merck & Co., Inc. | Hepatitis c virus conjugates |
| US20030092145A1 (en) * | 2000-08-24 | 2003-05-15 | Vic Jira | Viral vaccine composition, process, and methods of use |
| US7033593B2 (en) | 2000-09-22 | 2006-04-25 | Duke University | Immunogen comprising an HIV envelope protein, a ligand and H2 peptide |
| WO2002038177A2 (en) | 2000-11-10 | 2002-05-16 | Wyeth Holdings Corporation | Adjuvant combination formulations |
| US6906169B2 (en) | 2001-05-25 | 2005-06-14 | United Biomedical, Inc. | Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide |
| US20030224011A1 (en) * | 2001-05-29 | 2003-12-04 | Conley Anthony J | Hepatitis c virus conjugates |
| WO2002098368A2 (en) | 2001-06-07 | 2002-12-12 | Wyeth Holdings Corporation | Mutant forms of cholera holotoxin as an adjuvant |
| US7332174B2 (en) | 2001-06-07 | 2008-02-19 | Wyeth Holdings Corporation | Mutant forms of cholera holotoxin as an adjuvant |
| US20030135035A1 (en) * | 2001-08-09 | 2003-07-17 | Mark Shannon | Human ZZAP1 protein |
| EP1572894B1 (en) * | 2001-11-21 | 2016-04-13 | New York University | Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid beta, prion protein, amylin, alpha synuclein, or polyglutamine repeats for induction of an immune response thereto |
| DE60239042D1 (de) * | 2001-12-20 | 2011-03-10 | Randox Lab Ltd | Haptene, Immunogene, Antikörper und Konjugate für 2-oxo-3-hydroxy LSD |
| FR2833840B1 (fr) * | 2001-12-21 | 2010-06-18 | Rytek | Methodes et compositions pour le traitement de pathologies respiratoires |
| WO2003092619A2 (en) | 2002-04-30 | 2003-11-13 | Wyeth Holdings Corporation | Prevention and treatment of type 2 diabetes |
| CN1656725A (zh) * | 2002-05-28 | 2005-08-17 | 皇家飞利浦电子股份有限公司 | 由接收器对出错帧进行校正的方法 |
| KR20050101537A (ko) * | 2002-12-24 | 2005-10-24 | 뉴로켐 (인터내셔널) 리미티드 | 베타-아밀로이드 관련 질환의 치료를 위한 치료 제제 |
| NZ561879A (en) * | 2003-03-07 | 2009-05-31 | Wyeth Corp | Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
| EP1603950A2 (en) | 2003-03-17 | 2005-12-14 | Wyeth Holdings Corporation | Mutant cholera holotoxin as an adjuvant and an antigen carrier protein |
| CN100409896C (zh) * | 2003-03-31 | 2008-08-13 | 姚志彬 | 一种老年性痴呆疫苗及其制备方法 |
| SI2336147T1 (sl) | 2003-12-17 | 2014-08-29 | Janssen Alzheimer Immunotherapy | Konjugati nosilcev a beta imunogenih peptidov in postopki izdelave istih |
| SG149013A1 (en) * | 2003-12-17 | 2009-01-29 | Wyeth Corp | Immunogenic peptide carrier conjugates and methods of producing same |
| JP5045349B2 (ja) | 2007-10-01 | 2012-10-10 | パナソニック株式会社 | 左手系フィルタ |
-
2004
- 2004-12-17 SI SI200432170T patent/SI2336147T1/sl unknown
- 2004-12-17 PH PH1/2011/502391A patent/PH12011502391A1/en unknown
- 2004-12-17 US US10/583,503 patent/US8227403B2/en not_active Expired - Fee Related
- 2004-12-17 KR KR1020117020349A patent/KR101201120B1/ko not_active Expired - Fee Related
- 2004-12-17 TW TW100140530A patent/TWI379839B/zh not_active IP Right Cessation
- 2004-12-17 EP EP12157147.5A patent/EP2479184A3/en not_active Withdrawn
- 2004-12-17 BR BRPI0417689A patent/BRPI0417689A8/pt not_active IP Right Cessation
- 2004-12-17 SG SG2012043139A patent/SG182189A1/en unknown
- 2004-12-17 KR KR1020067014293A patent/KR101158147B1/ko not_active Expired - Fee Related
- 2004-12-17 CA CA002549552A patent/CA2549552A1/en not_active Abandoned
- 2004-12-17 EP EP12157140A patent/EP2460813A1/en not_active Withdrawn
- 2004-12-17 EP EP11151428.7A patent/EP2336147B1/en not_active Expired - Lifetime
- 2004-12-17 CN CN200480041798.9A patent/CN1934127B/zh not_active Expired - Fee Related
- 2004-12-17 DK DK11151428.7T patent/DK2336147T3/da active
- 2004-12-17 PT PT111514287T patent/PT2336147E/pt unknown
- 2004-12-17 PL PL11151428T patent/PL2336147T3/pl unknown
- 2004-12-17 EA EA200601168A patent/EA009559B1/ru not_active IP Right Cessation
- 2004-12-17 AU AU2004299512A patent/AU2004299512B2/en not_active Ceased
- 2004-12-17 ES ES11151428.7T patent/ES2474173T3/es not_active Expired - Lifetime
- 2004-12-17 EP EP04817081A patent/EP1699810A4/en not_active Withdrawn
- 2004-12-17 SG SG200809362-7A patent/SG149039A1/en unknown
- 2004-12-17 JP JP2006545618A patent/JP4696079B2/ja not_active Expired - Fee Related
- 2004-12-17 MY MYPI20045205A patent/MY144231A/en unknown
- 2004-12-17 EA EA200702209A patent/EA011239B1/ru not_active IP Right Cessation
- 2004-12-17 AR ARP040104758A patent/AR047062A1/es not_active Application Discontinuation
- 2004-12-17 MX MXPA06006821A patent/MXPA06006821A/es active IP Right Grant
- 2004-12-17 TW TW093139610A patent/TWI357414B/zh not_active IP Right Cessation
- 2004-12-17 WO PCT/US2004/044093 patent/WO2005058941A2/en not_active Ceased
- 2004-12-17 UA UAA200608020A patent/UA84728C2/ru unknown
-
2006
- 2006-06-08 CR CR8445A patent/CR8445A/es unknown
- 2006-06-12 IL IL176250A patent/IL176250A/en not_active IP Right Cessation
- 2006-06-13 NO NO20062765A patent/NO20062765L/no not_active Application Discontinuation
- 2006-06-15 EC EC2006006646A patent/ECSP066646A/es unknown
-
2007
- 2007-08-20 US US11/841,919 patent/US9095536B2/en not_active Expired - Fee Related
- 2007-08-20 US US11/841,993 patent/US20080299074A1/en not_active Abandoned
-
2011
- 2011-02-24 AU AU2011200785A patent/AU2011200785B2/en not_active Ceased
- 2011-05-26 IL IL213156A patent/IL213156A/en not_active IP Right Cessation
- 2011-07-07 US US13/178,428 patent/US9089510B2/en not_active Expired - Fee Related
-
2012
- 2012-02-14 US US13/396,543 patent/US9125847B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0417744A (pt) | métodos para conjugar um imunogene de peptìdeo e para induzir uma resposta imune em um indivìduo mamìfero, conjugado de portador de peptìdeo de imunogene-proteìna/polipeptìdeo e composição imunogênica | |
| BRPI0417689A8 (pt) | Método para conjugar um imonógeno de peptídeo, composição, conjugado, composição imunogênica, método para induzir uma resposta imune em um indivíduo mamífero, e, uso do conjugado | |
| US6472506B1 (en) | Polysaccharide-peptide-conjugates | |
| BRPI0417342A (pt) | fator estimulante de colÈnia de granulócitos glicopeguilado | |
| KR890004730A (ko) | G_7rh에 대한 면역반응을 유발시키고 포유동물을 면역 불임시키기 위한 제제 및 방법 | |
| BRPI0511751A (pt) | usos médicos de conjugados veìculos de peptìdeos de tnf não-humano | |
| BRPI0612654B8 (pt) | método para conjugar um sacarídeo a uma proteína, e, conjugado sacarídeo-proteína | |
| BRPI0417341A (pt) | fator ix glicopeguilado | |
| BRPI0815578B8 (pt) | Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer) | |
| AR074505A1 (es) | Vacuna de peptido ch3 de ige. inmunogeno. procedimiento. vector de expresion. celula huesped. | |
| NO975547D0 (no) | Vaksiner med modifiserte meningokokk/polysakkarid-konjugater | |
| DE69224988D1 (de) | Aminosäurederivat und bromacetyl-modifizierte peptide | |
| BR0113439A (pt) | Processo para a manufatura de um imunógeno para vacina, derivado de maleimida de peptìdeo de ige, uso do mesmo, conjugado adequado para uso em uma vacina e composição de vacina | |
| RU2008112497A (ru) | Коньюгат для иммунизации и вакцинации и способ повышения иммуногенности | |
| WO2019122050A1 (en) | Methods of immunization | |
| Reichel et al. | Synthetic carbohydrate-based vaccines: synthesis of an L-glycero-D-manno-heptose antigen–T-epitope–lipopeptide conjugate | |
| KR20150102003A (ko) | 당쇄 부가 링커, 당쇄 부가 링커 부분과 생리 활성 물질 부분을 함유하는 화합물 또는 그의 염, 및 이들의 제조 방법 | |
| KR20220160036A (ko) | 폴리뉴클레오티드-펩티드 컨쥬게이트를 포함하는 면역 유도제 및 그것을 포함하는 의약 조성물 | |
| Nodake et al. | Preparation and immunological characterization of β-lactoglobulin-amylose conjugate | |
| Taniguchi et al. | 2P-025 Direct observation of GroEL-substrate complexes by high-speed atomic force microscopy (Protein: Structure & Function, The 47th Annual Meeting of the Biophysical Society of Japan) | |
| TH111452A (th) | วิธีของการผลิตคอนจูเกตของตัวพาของอิมมูโนจีนิกเพปไทด์ | |
| Li | Explorations into the nature of insulin binding to oxidized dextran: this thesis was presented in partial fulfillment of the requirements for the degree of Master of Science in Chemistry at Massey University | |
| Kaita et al. | 2P-026 Transduction of fluctuations along internal mechanical network in molecular machines (Protein: Structure & Function, The 47th Annual Meeting of the Biophysical Society of Japan) | |
| BRPI0416913A (pt) | peptìdeo de eritropoietina, método de fabricação da eritropoietina peguilada, uso do peptìdeo e formulação farmacêutica | |
| TH115317A (th) | Ab อิมมูโนจีนิกเพปไทด์แคริเออร์คอนจูเกตและวิธีการผลิตสารเดียวกันนี้ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: WYETH (US) , ELAN PHARMA INTERNATIONAL LIMITED (IE Free format text: TRANSFERIDO DE: NEURALAB LIMITED |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. PAGAR RESTAURACAO. |
|
| B08H | Application fees: decision cancelled [chapter 8.8 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2260 DE 29/04/2014. |
|
| B25G | Requested change of headquarter approved |
Owner name: WYETH (US) , ELAN PHARMA INTERNATIONAL LIMITED (IE |
|
| B25A | Requested transfer of rights approved |
Owner name: WYETH (US) , CRIMAGUA LIMITED (IE) |
|
| B25A | Requested transfer of rights approved |
Owner name: WYETH (US) , JANSSEN ALZHEIMER IMMUNOTHERAPY (IE) |
|
| B25D | Requested change of name of applicant approved |
Owner name: JANSSEN ALZHEIMER IMMUNOTHERAPY (IE) , WYETH LLC ( |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: WYETH LLC (US) , JANSSEN SCIENCES IRELAND UC (IE) |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 14A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 NA RPI 2497 DE 13/11/2018 |